Akari Therapeutics (AKTX) Share-based Compensation (2012 - 2026)

Akari Therapeutics has disclosed Share-based Compensation across 10 years of filings, most recently posting $305000.0 for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $305000.0, down 69.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (up 361.82% YoY), and the FY2025 annual result was $2.9 million, up 966.42% from the prior year.
• Share-based Compensation came in at $305000.0 for Q1 2026 at Akari Therapeutics, down from $2.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q4 2025 to a low of -$718000.0 in Q4 2024.
• The 4-year median for Share-based Compensation is $305000.0 (2023), against an average of $539076.9.
• Across the five-year window, Share-based Compensation sank 336.18% in 2024 and surged 498.75% in 2025, its largest moves.
• Akari Therapeutics' Share-based Compensation stood at $304000.0 in 2023, then tumbled by 336.18% to -$718000.0 in 2024, then soared by 498.75% to $2.9 million in 2025, then sank by 89.35% to $305000.0 in 2026.
• The last three Share-based Compensation figures came in at $305000.0 (Q1 2026), $2.9 million (Q4 2025), and $685000.0 (Q3 2025), per Business Quant data.